Kevin W. MayoManaging Partner at Venture Genome LLC
Dr. Kevin Walker Mayo is Managing Director of Value Genome LLC, a value actualization firm assisting biotechnology innovators commercialize their assets by supporting market access, medical affairs, health economics and outcomes research, pricing and reimbursement endeavors. Prior to founding Value Genome LLC Kevin was most recently Vice President Gene Therapy Market Access for PTC Therapeutics supporting pre-commercialization activities AGIL-AADC to treat a disorder often referred to as Juvenile Parkinson’s disease.
Earlier in his career Kevin was Global Hemophilia Franchise Market Access Head for Baxalta (now Takeda). At Baxalta, Kevin lead a team of international market access experts responsible for negotiating with government and commercial payers to obtain pricing and formulary access for launching products. His responsibilities included conducting payer research and advisory boards to develop commercial strategies, developing and training his team upon value communication messages and negotiation tools and providing coordination for all health economics and outcomes research, pricing and reimbursement, tender management, advocacy and government affairs activities for a $6 billion portfolio. Kevin gained additional industry and consulting expertise in senior leadership roles with The Access Partnership, Endo Health Solutions, Bridgehead International, Daiichi Sankyo, Novartis Pharma AG and Pharmacia Corporation.
Kevin completed a Master’s degree in Neuropsychology and a Doctoral degree in Pharmaceutical Marketing and Administration. More recently Kevin augmented his business education by completing an Executive Juris Doctorate in Health Law and Policy. He has served on the adjunct faculties for the Mayes College of Healthcare Business and Policy (University of the Sciences) and the College of Population Health (Thomas Jefferson University) and is a frequent presenter at international market access conferences. Kevin received a Distinguish Service Award from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) for his contribution to the society.
Kevin Mayo is on Linkedin at www.linkedin.com/kevinmayomarketaccess